2nd Gene Therapy Potency Assay Summit 2024

The 2nd Gene Therapy Potency Summit is returning to Boston in July to support you in designing and validating robust potency assays to accelerate commercialization across a range of vector types and delivery modalities.

Featuring a speaker faculty of over 27 industry-leading experts from key biotech and pharmaceutical companies, this summit offers the most comprehensive agenda to date.

From case studies on phase-appropriate assay development to novel data presentations on cutting-edge HPLC and mass-spectrometry-based approaches, this year's program covers unique and diverse challenges that potency poses for complex gene therapies.

Uniting 100+ potency assay developers and solution providers from the likes of Sarepta Therapeutics, Ultragenyx, Sanofi, Spark Therapeutics, Vertex, Sangamo Therapeutics, and many others, this is your critical chance to learn from companies working on gene therapies from early development through to commercialized products.

Join us in July to engage with critical decision-makers, stay on top of industry trends, and gain key insights on ways to build out a solid potency strategy to ultimately prove to regulators that your product is efficacious.

URLs:
Website: https://go.evvnt.com/2239928-0?pid=176 
Tickets: https://go.evvnt.com/2239928-2?pid=176 
Brochure: https://go.evvnt.com/2239928-3?pid=176

Time: 9:00 AM - 5:30 PM

Prices:
Conference + 2 Workshops - Drug Developers: USD 4397.00,
Conference + 2 Workshops - Service Providers: USD 2999.00,
Conference Only - Drug Developers: USD 5297.00,
Conference Only - Service Providers: USD 3699.00

Speakers: Adnan Arnaout Senior Principal Scientist, Prevail Therapeutics, Alec Knapp Scientist, Tune Therapeutics, David Schwalb, Director - Analytical Development, Cell and Gene Therapies, Pacira Biosciences, Geeta Iyer, PD Manager, Assay Development, Beacon Therapeutics, Georgios Tsouchnikas, Head Of Assay Development, Hookipa Pharma Inc., Gillian Payne, Vice President - Analytical Development, Carbon Biosciences, Haiqing Yu, Senior Scientist and Analytical Team Manager, Sanofi, Hangtian Song, Associate Scientific Director, Bristol Myers Squibb, Hesham Nawar, Director - Analytical Development, Spark Therapeutics, Hwan June, Kang Senior Scientist, Neurocrine Biosciences, Isaac Hutchinson, Tech Transfer Specialist, Johnson and Johnson, Jie Li, Director, Vertex Pharmaceuticals, Katherine Bonnington, Scientist, Bristol Myers Squibb, Kayla Shumate, Scientist II, Bioanalysis and Bioassays, AskBio, Natalie Fekete Manager, Science and Industry Affairs, Alliance for Regenerative Medicine, Nicola Crawford, Director of Analytical Sciences, Barinthus Biotherapeutics, Ping Carlson, Director of Bioassay, Passage Bio, Qian Zhang, Scientist, Sangamo Therapeutics, Rajeev Boregowda, Associate Director, Bioassay and Molecular Analytical Development, Sanofi, Sangeet Lal, Senior Manager, Cell-Based Potency Assay Development, 4D Molecular Therapeutics, Susan Rutberg, Director - Bioassays and Molecular Biology, Sanofi, Susan Sleep, Director - Assay Development, Beacon Therapeutics, Ting He, Senior Scientist, AAV Pharmaceutical Development, Ultragenyx Pharmaceutical, Uditha DeAlwis Director – An,al Development and Quality Control, Sarepta Therapeutics, Xiaodong Fang, Director, Bioanalysis and Bioassays, AskBio, Youngmee Sul, Scientist, Tune Therapeutics